Clone 29F.1A12 is a rat antimouse monoclonal antibody widely used in mice for in vivo immune checkpoint blockade by targeting and blocking the PD1 receptor, thereby preventing its interaction with its ligands (PDL1 and PDL2).

Key in vivo applications include:

• Cancer immunotherapy research: Used to block PD1 signaling, 29F.1A12 enhances antitumor immune responses in mouse cancer models by promoting T cell activation and restoring antitumor immunity. Its efficacy has been evaluated alone or in combination with other immunotherapies to study synergy and mechanisms of checkpoint blockade.
• Mechanistic studies of T cell regulation: Utilized to dissect the role of PD1/PDL1 interactions in T cell exhaustion, tolerance, and activation, especially relevant in tumorbearing and chronic infection models.
• Comparative immunotherapy studies: Employed to evaluate the relative efficacy of different antiPD1 clones (e.g., compared versus RMP114 or J43) and to model clinical antiPD1 therapeutic antibodies, given its high PD1 blocking affinity.
• Genetic mouse models: Specifically applied to explore PD1 blockade effects in context of unique mutations or cancer syndromes; for example, in murine DNA polymerase mutator models, 29F.1A12 was used to study cancer onset and survival, with variable efficacy depending on the genetic context.

Additional relevant details:

• Isotype: Rat IgG2a.
• Does not deplete PD1+ cells: Acts by blocking receptorligand interaction rather than by cell depletion.
• Other use cases: While primarily for in vivo functional blockade, 29F.1A12 is also used in assays such as flow cytometry and immunohistochemistry to detect PD1.

In summary, 29F.1A12 is most commonly used in live mouse studies for immune checkpoint blockade, chiefly in cancer immunotherapy research, mechanistic T cell studies, and comparative immunotherapy modeling, with proven utility in a broad array of mouse disease models.

Commonly Used Antibodies and Proteins with 29F.1A12

29F.1A12 is a widely utilized rat antimouse PD1 (CD279) monoclonal antibody, frequently employed in both in vitro and in vivo research to block the PD1/PDL1 pathway in mouse models. In the literature, several other antibodies and proteins are commonly paired with 29F.1A12 for comprehensive pathway analysis, combination therapies, or to serve as positive/negative controls.

Frequently Used AntiPD1 Antibodies

• RMP114: Another rat antimouse PD1 clone, often compared directly with 29F.1A12. While both are used for in vivo PD1 blockade, 29F.1A12 generally exhibits higher binding affinity and more potent blocking activity at lower concentrations.
• RMP130: Also a rat antimouse PD1 clone, used for flow cytometry and sometimes in combination with 29F.1A12 to confirm PD1 expression and specificity in costaining experiments.
• J43: A hamster antimouse PD1 antibody, sometimes used as an alternative for PD1 blockade in mouse models, though less frequently paired with 29F.1A12 in the same studies.

Frequently Used AntiPDL1 Antibodies

• 10F.9G2: A rat antimouse PDL1 (B7H1) monoclonal antibody, commonly used alongside 29F.1A12 to model complete blockade of the PD1/PDL1 axis in both in vitro and in vivo settings.
• MIH6: Another rat antimouse PDL1 antibody, nearly equivalent to 10F.9G2 in blocking activity and often used interchangeably in combination with 29F.1A12 for comprehensive pathway inhibition.

Functional Proteins and Disease Models

• Recombinant PDL1: Used in functional assays to directly assess the blocking efficacy of 29F.1A12 on the interaction between PD1 and its ligands.
• Cytokines (e.g., IL2): Sometimes measured as downstream readouts of Tcell activation in studies using 29F.1A12 to demonstrate functional blockade of PD1 signaling.
• AntiCD28 antibodies: Occasional use in combination to provide costimulation and better model Tcell activation in vitro.

Summary Table

Key Takeaways

• 29F.1A12 is often used in combination with other antiPD1 clones (RMP114, RMP130, J43) or antiPDL1 clones (10F.9G2, MIH6) to fully interrogate the PD1/PDL1 pathway, validate specificity, and model combination immunotherapies.
• Recombinant PDL1 protein is sometimes employed in functional assays to directly measure blockade efficacy.
• Choice of antibody pair depends on the experimental question, with 29F.1A12 favored for its high affinity and strong blocking activity, especially when modeling human therapeutic responses in mice.

The 29F.1A12 monoclonal antibody clone targeting mouse PD1 (CD279) has generated several important findings across multiple studies, establishing it as a critical tool in immunology and cancer research.

Blocking Activity and Ligand Interaction

The most significant characteristic of 29F.1A12 is its exceptional blocking capability. This clone functions as a highly effective blocking antibody that prevents PD1 from interacting with its ligand PDL1. The blocking activity is so comprehensive that 29F.1A12 completely prevents PD1 detection by nearly all other antibody clones when used in competition assays. Among four tested antiPD1 clones, 29F.1A12 stands out as the most effective blocking antibody, completely displacing PDL1Fc binding at higher concentrations. At concentrations as low as 50 ng/ml, it can reduce PDL1Fc binding to PD1expressing cells.

Binding Specificity and Cell Recognition

Studies have confirmed that 29F.1A12 recognizes surface PD1 protein on live cells with high specificity. The clone successfully detects PD1 on live B16F10 melanoma cells and activated wildtype Tcells. When researchers FACSpurified PD1+ versus PD1 subpopulations, they found that Pdcd1 gene expression levels were more than 19fold enriched in PD1+ melanoma cell fractions and 6fold enriched in Tcell isolates.

The antibody demonstrates dual recognition patterns when costained with another clone (RMP130), showing dual positivity by nearly all PD1 antibodyreactive wildtype melanoma cells (90.8%) and PD1 overexpressing B16F10 cells (96.7%). Similarly, overlapping subpopulations of unactivated (57.2%) and activated wildtype Tcells (48.1%) were dually bound by both antibodies.

Culture Condition Effects

A notable finding is that 29F.1A12 reactivity varies significantly based on culture conditions. Both 29F.1A12 and RMP130 showed more than 3fold increased reactivity to live wildtype B16F10 cells in threedimensional (3D) versus twodimensional (2D) cultures. This aligns with the observation that the 29F.1A12 PD1 blocking antibody inhibits B16F10 melanoma growth in 3D tumor spheroid cultures but not in standard 2D cultures.

CrossReactivity with Dying Cells

An important caveat identified in the literature is that 29F.1A12 shows some crossreactivity with dying cells. While the clone maintains PD1 specificity for live cells, it demonstrates increased reactivity with fixable viability dyepositive (FVD+) cells, indicating reactivity with dead or dying cells. Researchers observed that PD1 staining with 29F.1A12 uncovered a forward scatterheight (FSCH) low population predominantly positive for PD1, which mainly contained dead cells.

Functional Applications

The 29F.1A12 antibody has been validated for blocking PD1 binding to its ligands in vivo, similar to other therapeutic clones like RMP114 and J43. This blocking capability has proven valuable in studying cancer immunotherapy, as PDL1 overexpression in tumors increases resistance to CD8 T cellmediated lysis, and blocking the PD1/PDL1 interaction can transiently arrest tumor growth in mouse models of melanoma.

Interestingly, while 29F.1A12 is primarily known as a blocking antibody, weak agonist activity was also detected with this clone, revealing additional functional complexity beyond its primary blocking mechanism.

Dosing regimens for clone 29F.1A12 (antiPD1 antibody) in mouse models are most commonly 100–200 μg per mouse administered intraperitoneally every 3 days for three doses, but regimens are tailored based on mouse strain, tumor model, and experimental goals.

Key dosing variations across mouse models:

• Standard regimen: 100–200 μg per mouse, intraperitoneal (IP), every 3 days for three doses.
• Alternative schedules: Some experiments adopt biweekly (twice per week) dosing or alter intervals (every 3–4 days, or weekly) depending on the desired duration of PD1 blockade, tumor kinetics, or mouse strain sensitivities.
• Dose adjustments: Lower doses (e.g., 50 μg every 3 days for four doses) or higher doses (up to 7.5 mg/kg, approx. 150–300 μg/mouse, twice weekly) are used based on antibody affinity, mouse weight, or to test efficacy thresholds.
• Dosing in BALB/c vs. C57BL/6: While the typical range remains 100–200 μg/mouse, publications note minor variations by genetic background. For example, some tumor models in BALB/c mice use up to 3week intervals or different booster schedules.

Factors influencing dosing variation include:

• Mouse strain and weight (BALB/c vs. C57BL/6 may differ slightly)
• Tumor model aggressiveness and burden
• Immune status (naïve vs. tumorbearing)
• Affinity of antibody constructs used
• Combination with other immunotherapies

For most studies, 100–200 μg per mouse, IP, every 3 days for 3 doses remains the reference regimen, but deviations are common based on experimental needs and mouse model specifics.